This study aimed to evaluate the long-term effects of metabolic surgery compared to GLP-1 RAs on macrovascular and microvascular outcomes in patients with type 2 diabetes and obesity. The researchers conducted a retrospective cohort study using data from a national healthcare database, including patients who underwent metabolic surgery or were treated with GLP-1 RAs between 2008 and 2021. The primary outcomes were the incidence of major adverse cardiovascular events (MACE), nephropathy, and retinopathy.

The study cohort consisted of 1,657 patients who underwent metabolic surgery and 2,275 patients treated with GLP-1 RAs. Propensity score matching was used to balance baseline characteristics between the two groups, including age, sex, BMI, duration of diabetes, and presence of comorbidities. The median follow-up period was 5.9 years. Data analysis involved Cox proportional hazards models to estimate the hazard ratios for the primary outcomes.

The study found that patients who underwent metabolic surgery had a 32% lower risk of all-cause mortality and a 35% lower risk of MACE compared to those treated with GLP-1 RAs. Additionally, the surgery group had a 47% lower risk of developing nephropathy and a 54% lower risk of retinopathy. These findings suggest that metabolic surgery not only improves glycemic control but also significantly reduces the risk of severe complications associated with type 2 diabetes and obesity.

These results have important implications for the management of patients with type 2 diabetes and obesity. While GLP-1 RAs are effective in controlling blood glucose levels, they may not provide sufficient protection against the long-term complications of diabetes. Metabolic surgery, by inducing significant and sustained weight loss, appears to offer superior protection against cardiovascular and microvascular complications.

For healthcare providers, this study emphasizes the need to consider metabolic surgery as a viable treatment option for patients with type 2 diabetes and obesity, particularly those at high risk for cardiovascular and renal complications. It also underscores the importance of a comprehensive treatment approach that includes lifestyle modifications, pharmacotherapy, and, when appropriate, surgical interventions.

The study’s observational design may introduce confounding factors that could influence the results. Although propensity score matching was used to adjust for baseline differences, unmeasured confounders may still exist. Additionally, the study did not assess the quality of life or patient-reported outcomes, which are important considerations in treatment decision-making. Future research should focus on randomized controlled trials to confirm these findings and explore the effects of metabolic surgery on other outcomes such as quality of life, healthcare utilization, and cost-effectiveness.

Share this post